Pemigatinib Pivotal Cholangiocarcinoma Data Published as FDA Weighs Approval
April 16th 2020Data from the phase II FIGHT-202 study of pemigatinib in advanced or metastatic FGFR2-positive cholangiocarcinoma have been published as the FDA considers a new drug application for the treatment in this setting.
Read More
Analyses Underscore Extent of Frontline Maintenance Niraparib Benefit in Ovarian Cancer
April 11th 2020The success of frontline maintenance niraparib in the phase III PRIMA trial extends to meeting biomarker-defined and other secondary endpoints and showing positive patient-reported outcomes.
Read More
Leronlimab COVID-19 Trial Treats First Patients
April 7th 2020The first 2 patients with COVID-19 have received treatment in a phase II trial exploring the investigational agent leronlimab, a CCR5 antagonist which has been advancing through the pipeline as a treatment for patients with triple-negative breast cancer.
Read More
Analysis Pinpoints Veliparib Antitumor Activity in Ovarian Cancer
April 6th 2020Adding veliparib to frontline induction chemotherapy increased complete and CA-125 responses compared with chemotherapy alone in patients with high-grade serous ovarian cancer, according to an exploratory analysis of the phase III VELIA trial.
Read More
KTE-X19 Pivotal MCL Data Published in NEJM as FDA Weighs Approval
April 4th 2020Findings from the pivotal phase II ZUMA-2 trial of KTE-X19 as a treatment for adult patients with relapsed/refractory mantle cell lymphoma were published in the New England Journal of Medicine, as the FDA considers a biologics license application for the CAR T-cell therapy for an approval in this setting.
Read More